Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,183,237
  • Shares Outstanding, K 58,688
  • Annual Sales, $ 43,950 K
  • Annual Income, $ -154,940 K
  • 60-Month Beta 1.10
  • Price/Sales 74.48
  • Price/Cash Flow N/A
  • Price/Book 9.50
Trade MRUS with:

Options Overview Details

View History
  • Implied Volatility 48.71% ( -0.32%)
  • Historical Volatility 104.30%
  • IV Percentile 6%
  • IV Rank 14.43%
  • IV High 147.11% on 05/16/24
  • IV Low 32.12% on 08/14/23
  • Put/Call Vol Ratio 6.36
  • Today's Volume 184
  • Volume Avg (30-Day) 2,395
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 28,376
  • Open Int (30-Day) 26,072

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.77
  • Number of Estimates 8
  • High Estimate -0.68
  • Low Estimate -0.89
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.60 +27.32%
on 05/21/24
61.61 -11.96%
on 05/24/24
+10.33 (+23.53%)
since 05/17/24
3-Month
39.27 +38.12%
on 04/19/24
61.61 -11.96%
on 05/24/24
+9.92 (+22.38%)
since 03/18/24
52-Week
19.81 +173.87%
on 10/30/23
61.61 -11.96%
on 05/24/24
+28.09 (+107.42%)
since 06/16/23

Most Recent Stories

More News
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 1.0200 (+0.99%)
CADL : 6.72 (-6.93%)
AZN : 78.42 (-1.12%)
MRUS : 54.24 (-2.74%)
LTRN : 4.69 (-4.48%)
ONC.TO : 1.39 (unch)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
CADL : 6.72 (-6.93%)
AZN : 78.42 (-1.12%)
MRUS : 54.24 (-2.74%)
LTRN : 4.69 (-4.48%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
RHHBY : 34.9800 (+1.16%)
MRUS : 54.24 (-2.74%)
MGNX : 4.12 (-3.96%)
IMRX : 1.4800 (-3.58%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
PYXS : 3.42 (-6.56%)
AZN : 78.42 (-1.12%)
LLY : 891.46 (+0.73%)
MRUS : 54.24 (-2.74%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.39 (unch)
ONCY : 1.0200 (+0.99%)
PYXS : 3.42 (-6.56%)
AZN : 78.42 (-1.12%)
LLY : 891.46 (+0.73%)
MRUS : 54.24 (-2.74%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
PYXS : 3.42 (-6.56%)
AZN : 78.42 (-1.12%)
LLY : 891.46 (+0.73%)
MRUS : 54.24 (-2.74%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...

ONC.TO : 1.39 (unch)
ONCY : 1.0200 (+0.99%)
MRUS : 54.24 (-2.74%)
GH : 29.94 (-1.84%)
MDT : 79.75 (-0.25%)
NVDA : 135.58 (+3.51%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 26, 2023 – USA News Group  –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
MRUS : 54.24 (-2.74%)
GH : 29.94 (-1.84%)
MDT : 79.75 (-0.25%)
NVDA : 135.58 (+3.51%)
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments

USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
MRUS : 54.24 (-2.74%)
GH : 29.94 (-1.84%)
MDT : 79.75 (-0.25%)
NVDA : 135.58 (+3.51%)
Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade

The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

MRUS : 54.24 (-2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is...

See More

Key Turning Points

3rd Resistance Point 57.47
2nd Resistance Point 56.69
1st Resistance Point 55.47
Last Price 54.24
1st Support Level 53.47
2nd Support Level 52.69
3rd Support Level 51.47

See More

52-Week High 61.61
Last Price 54.24
Fibonacci 61.8% 45.64
Fibonacci 50% 40.71
Fibonacci 38.2% 35.77
52-Week Low 19.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar